获取途径

作者

Yan Zhao, Litao Zhang, Liming Wu, Bin Yang, Jinyan Wang, Yumei Li, Qingchun Diao, Jingyi Li, Qing Sun, Xiaohong Zhu, Xiaoyong Man, Lihua Wang, Yanyan Feng, Tao Cai, Huiming Zeng, Linfeng Li, Jianyun Lu, Hong Ren, Fuqiu Li, Qianjin Lu, Xiaohua Tao, Rong Xiao, Chao Ji, Jing Sun, Yanping Qiu, Bo Chen, Jianzhong Zhang

作者单位

Affiliations ¹ From the Department of Dermatology, Peking University People's Hospital, Beijing, China. ² Department of Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, China. ³ Department of Dermatology, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China. ⁴ Department of Dermatology, Dermatology Hospital of Southern Medical University, Guangzhou, China. ⁵ Department of Dermatology, Ningbo No. People's Hospital (Jiangnan University Medical Center), Wuxi, China. ¹¹ Department of Dermatology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. ¹² Department of Dermatology, Central Hospital Affiliated to Shandong First Medical University, Jinan, China. ¹³ Department of Dermatology, Chengdu Second People's Hospital, Chengdu, China. ¹⁴ Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. ¹⁵ Department of Dermatology, The First Affiliated Hospital of Hainan Medical University, Haikou, China. ¹⁶ Department of Dermatology, Beijing Friendship Hospital, Capital Medical University, Beijing, China. ¹⁷ Department of Dermatology, The Third Xiangya Hospital of Central South University, Changsha, China. ¹⁸ Department of Dermatology, The First People's Hospital of Lianyungang, Lianyungang, China. ¹⁹ Department of Dermatology, The Second Hospital of Jilin University, Changchun, China. ²⁰ Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China. ²¹ Key Laboratory of Basic and Translational Research on Immune-Mediated Skin Diseases, Chinese Academy of Medical Sciences, Nanjing, China. ²² Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Nanjing, China. ²³ Department of Dermatology, Zhejiang Provincial People's Hospital, Hangzhou, China. ²⁴ Department of Dermatology and Venereology, The Second Xiangya Hospital of Central South University, Changsha, China. ²⁵ Department of Dermatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China. ²⁶ Keymed Biosciences (Chengdu) Co., Ltd., Chengdu, China. Hospital, Ningbo, China. ⁶ Department of Dermatology, Affiliated Hospital of Jiangsu University, Zhenjiang, China. ⁷ Department of Dermatology, Chongqing Traditional Chinese Medicine Hospital, Chongqing, China. ⁸ Department of Dermatovenereology, West China Hospital of Sichuan University, Chengdu, China. ⁹ Department of Dermatology, Qilu Hospital of Shandong University, Jinan, China. ¹⁰ Department of Dermatology, Wuxi No

刊名

Dermatitis : contact, atopic, occupational, drug

年份

2025

ISSN

2162-5220

摘要

Background: Stapokibart has been approved for the treatment of adults with atopic dermatitis in China. Objective: To report long-term efficacy of stapokibart in patients with moderate-to-severe AD. Methods: This post hoc analysis included 237 adult patients from a phase 3 trial who received stapokibart 300 mg every 2 weeks during the 16-week double-blind period and continued with the same dose of stapokibart in the subsequent 36-week maintenance period. Results: At week 20, 100% and 92.2% of ...更多

Background: Stapokibart has been approved for the treatment of adults with atopic dermatitis in China. Objective: To report long-term efficacy of stapokibart in patients with moderate-to-severe AD. Methods: This post hoc analysis included 237 adult patients from a phase 3 trial who received stapokibart 300 mg every 2 weeks during the 16-week double-blind period and continued with the same dose of stapokibart in the subsequent 36-week maintenance period. Results: At week 20, 100% and 92.2% of patients who achieved coprimary endpoints at week 16 retained their EASI-75 and IGA 0/1 response, respectively. At week 52, these figures reached 99.0% and 87.0%, respectively. Among those who had not achieved EASI-75 or IGA 0/1 at week 16, 65.4% achieved EASI-75 and 18.1% achieved IGA 0/1 at week 20, and reached 86.8% and 50.0% at week 52, respectively. The patient-reported outcomes also improved sustainedly. Conclusions: Long-term stapokibart treatment induced sustained clinical improvements in adult patients with moderate-to-severe AD, regardless of their initial response to 16-week treatments.收起

文献类型

期刊